www.fdanews.com/articles/87223-cubist-pharmaceuticals-outperform-target-price-raised
CUBIST PHARMACEUTICALS 'OUTPERFORM,' TARGET PRICE RAISED
May 31, 2006
Analysts at RBC Capital Markets reiterate their "outperform" rating on Cubist Pharmaceuticals. The target price has been raised from $25 to $33.
Newratings